PROJECT 3 One of the goals of the National Institute of Environmental Health Sciences Superfund Research Program (SRP) is the development of methods and technologies to detect, assess and evaluate the effects of toxic substances on human health. To address the issue of high analysis costs for assessing toxic substances in the environment as well as the need for measuring indicators of exposure to humans, this project will develop new immunoassays, improve the utility of the assays, and apply them (in collaboration with other investigators in the UC Davis SRP Center). A complement to gas or liquid chromatography (GC or LC) coupled to mass spectrometry (MS), immunoassays are characterized by their speed, sensitivity, high throughput and low cost, which is underscored by their long history of use in clinical diagnostics. This project proposes three aims:
Aim I is to make strategic improvements to an emerging antibody technology (called VHH or nanobody), which will vastly change the field of immunodiagnostics, including testing for small environmental molecules.
Aim II is to develop new assays for compounds of concern to the community partner, identified by the Bioremediation project (Project 1), and the SRP that can be used to assess hazardous chemicals in the environment and in humans. Some of the high-priority compounds for assay development include coumarin rodenticides, polychlorinated biphenyls (PCBs), and pesticides and their degradation products. In this same realm of antibody development, the second aim includes a collaboration with Projects 4 and 5 to develop antibodies for protein targets needed to enhance the throughput of Western blot technology. Western blots are critical components of diagnostic testing to identify the effects of toxic chemical exposure. With improved efficiency, more chemicals can be screened and a better grasp of the toxic effects can be discerned.
Aim III is to advance field methods for chemical detection by developing new immunodiagnostic technologies and applying them to real-world sampling needs. Through a collaboration with the Lab-on-a-Chip Nanosensing Platforms project (Project 2), classical antibodies as well as newly developed VHH reagents will be used in novel biosensors and membrane-based platforms. These new technologies will emphasize field portability, high sample throughput, and ease of use by the end-user, in order augment the Program's research translation and community engagement efforts. Such technologies will be used to empower communities to collect data in response to their environmental chemical concerns. Ultimately, the immunoassays developed in this project will be valuable tools for stakeholders who wish to detect chemical exposures and biomarkers of their toxicity.

Public Health Relevance

PROJECT 3 Identifying the exposures of people to chemicals in the environment is critical to protecting human health. The assays developed in Project 3 will facilitate the ability of stakeholders to measure chemical exposures or biomarkers of the effect of such exposures, providing needed data to inform industry, government, policy makers and the general public.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
2P42ES004699-29A1
Application #
9259776
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-03-31
Support Year
29
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Harris, Todd R; Kodani, Sean; Rand, Amy A et al. (2018) Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury. Mol Pharmacol 94:834-841
Bever, Candace S; Rand, Amy A; Nording, Malin et al. (2018) Effects of triclosan in breast milk on the infant fecal microbiome. Chemosphere 203:467-473
Zheng, Jing; McKinnie, Shaun M K; El Gamal, Abrahim et al. (2018) Organohalogens Naturally Biosynthesized in Marine Environments and Produced as Disinfection Byproducts Alter Sarco/Endoplasmic Reticulum Ca2+ Dynamics. Environ Sci Technol 52:5469-5478
Lakkappa, Navya; Krishnamurthy, Praveen T; Yamjala, Karthik et al. (2018) Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development. J Pharm Biomed Anal 149:457-464
Guedes, A G P; Aristizabal, F; Sole, A et al. (2018) Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis. J Vet Pharmacol Ther 41:230-238
Heikenfeld, J; Jajack, A; Rogers, J et al. (2018) Wearable sensors: modalities, challenges, and prospects. Lab Chip 18:217-248
Minaz, Nathani; Razdan, Rema; Hammock, Bruce D et al. (2018) An inhibitor of soluble epoxide hydrolase ameliorates diabetes-induced learning and memory impairment in rats. Prostaglandins Other Lipid Mediat 136:84-89
Lassabe, Gabriel; Kramer, Karl; Hammock, Bruce D et al. (2018) Noncompetitive Homogeneous Detection of Small Molecules Using Synthetic Nanopeptamer-Based Luminescent Oxygen Channeling. Anal Chem 90:6187-6192
?ertíková Chábová, V?ra; Kujal, Petr; Škaroupková, Petra et al. (2018) Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney Blood Press Res 43:329-349
Kodani, Sean D; Bhakta, Saavan; Hwang, Sung Hee et al. (2018) Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. Bioorg Med Chem Lett 28:762-768

Showing the most recent 10 out of 1149 publications